Hypofibrinogenemic Hemorrhage in Acute Myelogenous Leukemia Treated with Heparin
Authors: WILLIAM G. BAKER
Journal: Annals of Internal Medicine (1964)

Case Studies1 July 1964Hypofibrinogenemic Hemorrhage in Acute Myelogenous Leukemia Treated with HeparinWith Autopsy Findings of Widespread Intravascular ClottingWILLIAM G. BAKER, M.D., NILS U. BANG, M.D., RALPH L. NACHMAN, M.D., FARRO RAAFAT, M.D., HERBERT I. HOROWITZ, M.D.WILLIAM G. BAKER, M.D.Search for more papers by this author, NILS U. BANG, M.D.Search for more papers by this author, RALPH L. NACHMAN, M.D.Search for more papers by this author, FARRO RAAFAT, M.D.Search for more papers by this author, HERBERT I. HOROWITZ, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-61-1-116 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptHemorrhage is a frequent complication of acute leukemia. A recent review of acute leukemia presented evidence of bleeding in 66% of 322 cases and showed that it was the principal cause of death in 44% (1). The pathogenesis of hemorrhage in most cases of acute leukemia is quite obvious: leukemic replacement of normal bone marrow results in severe thrombocytopenia (2, 3). Occasionally, the cause is more obscure, being variously ascribed to qualitative platelet deficiencies (4), vascular endothelial damage from anoxia or lysins (5), leukemic infiltration of vessel walls (6), or circulating anticoagulants (7, 8). Recent studies report that in certain...References1. BOGGSWINTROBECARTWRIGHT DRMRGE: The acute leukemias. Medicine (Baltimore) 41: 163, 1962. CrossrefMedlineGoogle Scholar2. MINOTBUCKMAN GRTE: The blood platelets in the leukemias. Amer. J. Med. Sci. 169: 477, 1925. CrossrefGoogle Scholar3. GAYDOSFREIREICHMANTEL LAEJN: The quantitative relation between the platelet count and hemorrhage in patients with acute leukemia. New Eng. J. Med. 266: 905, 1962. CrossrefMedlineGoogle Scholar4. PERRYBAKER SM: Coagulation defects in leukemia. J. Lab. Clin. Med. 50: 229, 1957. MedlineGoogle Scholar5. BIGGSMACFARLANE RPRG: Human Blood Coagulation and Its Disorders, Third Edition, Blackwell, Oxford, 1962, p. 272. Google Scholar6. FRITZFORKNERFREIREICHFREITHOMAS RDCEEJELB: Association of fatal intracranial hemorrhage and "blastic crisis" in patients with acute leukemia. New Eng. J. Med. 261: 59, 1959. CrossrefMedlineGoogle Scholar7. RISAK E: Die fibrinopenie. Z. Klin. Med. 128: 605, 1935. Google Scholar8. WELSHROBINSONBIRD JDCRM: Serial fibrinogen determinations in patients with acute leukemia. Amer. J. Med. Sci. 241: 207, 1961. CrossrefMedlineGoogle Scholar9. GIRAUDGAZALLATOURIZORNLEVYBARGONRIBSTEIN GPHPAPM: Syndrome hémorrhagique mortel par fibrinolyse aiguë au cours d'une leucose. Sang 25: 628, 1954. MedlineGoogle Scholar10. PISCIOTTASCHULZ AVEJ: Fibrinolytic purpura in acute leukemia. Amer. J. Med. 19: 824, 1955. CrossrefMedlineGoogle Scholar11. COOPERBERGNEIMAN AAGM: Fibrinogenopenia and fibrinolysis in acute myelogenous leukemia. Ann. Intern. Med. 42: 706, 1955. LinkGoogle Scholar12. HILLESTAD LK: Acute promyelocytic leukemia. Acta Med. Scand. 159: 189, 1957. CrossrefMedlineGoogle Scholar13. BERNARDMATHEBOULAYCEOARDCHOME JGJBJ: La leucose aiguë à promyélocytes. Schweiz. Med. Wschr. 89: 604, 1959. MedlineGoogle Scholar14. FISHERRAMOTKREISLER SBB: Fibrinolysis in acute leukemia. Israel Med. J. 19: 195, 1960. MedlineGoogle Scholar15. PERUGINIGOBBIASCARIGHISLERI SFEG: Fibrinolytic purpura in acute myelogenous leukemia. Haemat. Lat. 4: 15, 1961. Google Scholar16. NILSSON I: Discussion in Thromb. Diath. Haemorrh. 6: (suppl. 1) 323, 1961. MedlineGoogle Scholar17. ROSENTHAL RL: Acute promyelocytic leukemia associated with hypofibrinogenemia. Blood 21: 495, 1963. CrossrefMedlineGoogle Scholar18. DIDISHEIMTROMBOLDVANDERVOORTMIBASHANWINTROBECARTWRIGHT PJSRLRSMMGE: Fibrinogen and factor V deficiencies in acute promyelocytic leukemia (APL). Fed. Proc. 22: 329, 1963. (Abstract) Google Scholar19. HOROWITZWILCOXFUJIMOTO HIWPMM: Assay of plasma thromboplastin antecedent (PTA) with artificially depleted normal plasma. Blood 22: 35, 1963. CrossrefMedlineGoogle Scholar20. Fowell AH: Turbidometric method of fibrinogen assay: results with the Coleman Junior Spectrophotometer. Amer. J. Clin. Path. 25: 340, 1955. CrossrefMedlineGoogle Scholar21. KOLLERLOELIGERDUCKERT FAF: Experiments on a new clotting factor, factor VII. Acta Haemat. (Basel) 6: 1, 1961. CrossrefGoogle Scholar22. SHERRYLINDEMEYERFLETCHERALKJAERSIG SRIAPN: Studies on enhanced fibrinolytic activity in man. J. Clin. Invest. 38: 810, 1959. CrossrefMedlineGoogle Scholar23. NIEWIAROWSKIKOWALSKI SE: Un nouvel anticoagulant derive du fibrinogen. Nouv. Rev. Franc. Hémat. 13: 320, 1958. Google Scholar24. WARNERBRINKHOUSSEEGERSSMITH EDKMWHHP: Further experience with the use of thrombin as a haemostatic agent. Proc. Soc. Exp. Biol. Med. 41: 655, 1939. CrossrefGoogle Scholar25. BRINKHOUSGERATZ KMJD: "Paradoxical" thrombosis and hemorrhage (Penick's syndrome). Some intermediary sequences in its pathogenesis, in Anticoagulants and Fibrinolysis, Edited by MACMILLAN, R. L., MUSTARD, J. F., Lea & Febiger, Philadelphia, 1961, p. 28. Google Scholar26. SPAETKROPATKIN THM: Effect of intravenous blood thromboplastin intermediates on clotting in rats. Amer. J. Physiol. 195: 77, 1958. CrossrefMedlineGoogle Scholar27. MCKAYSHAPIRO DGSS: Alterations in the blood coagulation system induced by bacterial endotoxin. 1. In vivo (generalized Schwartzman reaction). J. Exp. Med. 107: 353, 1958. CrossrefMedlineGoogle Scholar28. BRINKHOUSPENICK KMGD: Some systemic alterations in clotting factors following local tissue injury. Proceedings, First Int. Conf. Thrombosis and Embolism, Benno Schwabe and Co., Basel, 1955. Google Scholar29. FLETCHERALKJAERSIGSHERRY APNS: Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J. Clin. Invest. 41: 896, 1962. CrossrefMedlineGoogle Scholar30. FLETCHERALKJAERSIGSHERRY APNS: Fibrinolytic mechanism and the development of thrombolytic therapy. Amer. J. Med. 33: 738, 1962. CrossrefMedlineGoogle Scholar31. ALKJAERSIGFLETCHERSHERRY NAPS: Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibriolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization. J. Clin. Invest. 41: 917, 1962. CrossrefMedlineGoogle Scholar32. ALKJAERSIGFLETCHERSHERRY NAPS: Epsilonaminocaproic acid. An inhibitor of plasminogen activation. J. Biol. Chem. 234: 832, 1959. CrossrefMedlineGoogle Scholar33. ABLONDIDERENZO FBEC: Mechanisms of clot lysis by streptokinase and effects of epsilon-aminocaproic acid. Proc. Soc. Exp. Biol. Med. 102: 717, 1959. CrossrefMedlineGoogle Scholar34. MERSKEYJOHNSONWOHL CAH: Heparin treatment of bleeding. Lancet I: 611, 1963. (Letter). CrossrefGoogle Scholar35. VON FRANCKENJOHANSSONOLSSONZETTERQUIST ILPE: Heparin treatment of bleeding: clinical observations. Lancet I: 70, 1963. CrossrefGoogle Scholar36. CAHALANEHORN SFRC: Thrombotic thrombocytopenic purpura of long duration. Amer. J. Med. 27: 333, 1959. CrossrefMedlineGoogle Scholar37. MEACHAMORBISONHEINLESTEELESHAEFER GCJLRWHJJA: Thrombotic thrombocytopenic purpura: a disseminated disease of arterioles. Blood 6: 706, 1951. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, New YorkFrom the Departments of Medicine and Pathology, New York Hospital-Cornell Medical Center and Second (Cornell) Medical Division, Bellevue Hospital, New York City, New York. Supported in part by research grant HE-05746 from the United States Public Health Service, Bethesda, Maryland.Dr. Nachman performed this work while under tenure of the Public Health Service research training grant 2A-5337 from the National Institute of Arthritis and Metabolic Disease, United States Public Health Service, Bethesda, MarylandRequests for reprints should be addressed to Ralph L. Nachman, M.D., The New York Hospital-Cornell Medical Center, 525 East 68th Street, New York, New York 10021. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByAcute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute LeukemiaBleeding and Thrombosis in Hematologic NeoplasiaAcute promyelocytic leukemia: where did we start, where are we now, and the futureBleeding and Thrombosis in Hematologic NeoplasiaAcute promyelocytic leukaemia in the alltrans retinoic acid eraClinical Aspects of Acute Promyelocytic Leukemia and Response to Retinoid TherapyAcute Promyelocytic Leukemia: New Insights into Diagnosis and TherapyNew Insights into the Pathogenesis of Coagulation Dysfunction in Acute Promyelocytic LeukemiaRetinoids in Cancer TreatmentBleeding complications and coagulopathy in acute leukaemiaHematologic Causes of Intracerebral Hemorrhage and Their TreatmentThe Coagulopathy of Acute LeukemiaThe bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrinationBeneficial effect of heparin in the management of patients with APLTissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulationEpsilon-Aminocaproic Acid in the Treatment of Patients with Acute Promyelocytic Leukemia and Acquired Alpha-2-Plasmin Inhibitor DeficiencyBRADFORD S. SCHWARTZ, M.D., ELIOT C. WILLIAMS, M.D.; Ph.D., MAUREEN G. CONLAN, M.D., DEANE F. MOSHER, M.D.Acute promyelocytic leukemia in 57 previously untreated patientsHYPOFIBRINOGENEMIA DUE TO INCREASED FIBRINOLYSIS IN TWO PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIAAntithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparinAntithrombin III and anti-activated factor × activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparinAcute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variantCase Report Hepatic Vein Thrombosis (Acute Budd-Chiari Syndrome) in Acute LeukemiaAcute promyelocytic leukemia—clinical management of 15 patientsAcute promyelocytic leukemiaAcute promyelocytic leukemiaPeripheral microthrombotic purpura associated with acute promyelocytic leukemia in pregnancyPROCOAGULANT ACTIVITY OF LEUKOCYTESAcute hypergranular promyelocytic leukaemiaPathologic cells as procoagulant substance of disseminated intravascular coagulation syndrome in acute promyelocytic leukemiaThe Procoagulant Factor of Leukaemic Promyelocytes: Demonstration of Immunologic Cross Reactivity with Human Brain Tissue FactorDie Hämostasestörung der akuten LeukämieACUTE PROMYELOCYTIC LEUKAEMIA: HAEMORRHAGIC MANIFESTATION AND MORPHOLOGIC CRITERIAFibrinogen survival and fibrinolysis in acute leukemiaClinical and morphological correlations in acute promyelocytic leukemiaThe Prophylactic Treatment of Thrombocytopenic Leukemic Patients with Platelets: a Double Blind StudyExperimental venous thrombosis in agranulocytic rabbitsLeukemic cellular thrombi in pulmonary blood vessels.Subleukemic myelogenous leukemia following chloramphenicol-induced aplastic anemiaRelationship between Blast-Cell Morphology and Occurrence of a Syndrome of Disseminated Intravascular CoagulationHeparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemiaReferenceThe Role of Heparin in the Management of Consumption CoagulopathyDiffuse Intravascular Coagulation: An Analysis of a Basic Mechanism of DiseaseI. PodiumgesprächPhysiology and Biochemistry of FibrinolysisFactor VIII (Anti-hemophilic factor)Recognition and treatment of intravascular coagulationHYPOFIBRINOGENAEMIA IN ACUTE LEUKAEMIA WITH EXTENSIVE FIBRINOUS PERICARDITISProaccelerin Levels in Leukemias.Intravascular coagulation in acute stem cell leukemia successfully treated with heparinA Coagulation Study in Patients with NeuroblastomaVariants of Acute LeukemiaHYPOFIBRINOGENÆMIA WITHOUT INCREASED FIBRINOLYSIS IN LEUKÆMIAReferencesBleeding Due to Increased Intravascular Blood Coagulation 1 July 1964Volume 61, Issue 1Page: 116-123KeywordsAnticoagulantsHemorrhageHeparinHospital medicineMedical servicesMetabolic disordersPathogenesisPlateletsResearch grantsRivers Issue Published: 1 July 1964 PDF DownloadLoading ...